Drug Approval | March 28, 2024
Biocon to obtain approval for diabetes drug, Liraglutide in UK
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus
The pilot plant is focused on scaling up beverage production and will support applications
More than 10,000 scientific publications containing EUDRAGIT
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Over 34 lakh children and 6 lakh pregnant women were administered vaccine doses during the first 2 rounds of IMI 5.0 campaign across the country
Collaboration combines clinical research expertise with artificial intelligence capabilities to help drug developers better understand the probability of clinical success for their assets
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Science communication brings behavioural changes
Subscribe To Our Newsletter & Stay Updated
